Citi analyst Patrick Donnelly downgraded Qiagen (QGEN) to Neutral from Buy with a price target of $50, down from $55. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. It sees Qiagen shares remaining in a trading range given its challenging comparisons and margin dilution from recent acquisitions.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen price target lowered to EUR 46 from EUR 50 at Berenberg
- Qiagen price target lowered to $48 from $50 at TD Cowen
- Qiagen’s Hold Rating: Solid Q3 Performance Overshadowed by Uncertainties and Mixed Growth Outlook
- Qiagen’s Hold Rating: Navigating Market Crosswinds and Valuation Concerns
- Qiagen price target lowered to $46 from $49 at Baird